Dr. Kunsong Li serves as Vice President and Chief Oncologist at Tianhe Hospital, affiliated with Guangdong Second Provincial General Hospital. He is a member of the American Society of Clinical Oncology (ASCO) and the Chinese Society of Clinical Oncology (CSCO), as well as an Executive Committee member of the Rare Tumors Specialty Committee of CSCO.

From 2021 to 2023, Dr. Li served as the Vice President of Zhaoqing Central People's Hospital. During this period, he established the Oncology

Department and founded the "Breast Tumor Chronic Disease Management Center." His leadership led to the center receiving provincial-level recognition for its "Chemotherapy-Induced Nausea and Vomiting (CINV) Standard Care Ward (No Vomiting Ward)" and "Cancer Pain Standard Management Ward (No Pain Ward)."

Dr. Li has over a decade of experience in clinical practice, education, and research in the field of malignant tumor management. His clinical focus includes the standardized treatment of lung cancer and breast cancer. He has performed over 1,000 local puncture treatments and more than 200 chest wall tumor ablation therapy. In addition, he has treated over 10,000 patients with malignant tumors, excelling in devising systematic and personalized anti-tumor treatment plans for patients. Notably, after treatment under his guidance, the 5-year overall survival rate (OS) and the progression-free survival (PFS) of the patients surpass the international averages.

​Dr. Li's research focuses on the comprehensive treatment of chest wall tumors, with a special emphasis on the use of oncolytic viruses in treating malignant chest wall tumors. As of now, he has participated in 3 provincial research projects and co-authored 2 specialized monographs. Additionally, Dr. Li has published numerous academic papers, and his scientific research findings have been presented in a poster at the 2020 World Conference on Lung Cancer (WCLC).